Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmentally Safe and Just Pharmacy: A Framework and Action Plan for Operating within the Earth System Boundary for Novel Entities.

Environmental science & technology·2026
Same author

A mode-of-Action-Based Approach for Predicting Cross-Species Sensitivity of Freshwater Invertebrates to Chemicals.

Integrated environmental assessment and management·2026
Same author

A robust method to quantify pharmaceuticals for the United Nations endorsed Global Estuaries Monitoring (GEM) Programme.

Marine pollution bulletin·2025
Same author

Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus.

The Lancet. Oncology·2024
Same author

Pharmaceutical Pollution of the English National Parks.

Environmental toxicology and chemistry·2024
Same author

Are pharmaceutical residues in crops a threat to human health?

Journal of toxicology and environmental health. Part A·2024

Related Experiment Videos

Enhancing pharmaceutical hazard assessment with machine learning mobility models.

Nahum Ashfield1, Jun Li1, Alistair B A Boxall1

  • 1Department of Environment and Geography, University of York, York, YO10 5NG, UK. jun.li@york.ac.uk.

Environmental Science. Processes & Impacts
|July 10, 2026
PubMed
Summary

A new machine learning model accurately predicts pharmaceutical sorption, crucial for environmental risk assessment. This tool helps classify the mobility of many active pharmaceutical ingredients across different soil types.

Related Experiment Videos

Area of Science:

  • Environmental Chemistry
  • Computational Toxicology
  • Soil Science

Background:

  • Limited experimental sorption data hinders pharmaceutical environmental hazard assessment.
  • Existing predictive models for sorption lack reliability, especially for ionizable compounds and neglecting sorbent properties.

Purpose of the Study:

  • To develop an optimized and accessible random forest machine learning model for predicting pharmaceutical sorption coefficients.
  • To capture soil-dependent variance in the environmental mobility of active pharmaceutical ingredients.

Main Methods:

  • Developed a random forest machine learning model to predict linear sorption coefficients (log Kd).
  • Validated model performance against external literature (R² = 0.60) and industry data (R² = 0.29).
  • Predicted log Kd for 1661 pharmaceuticals, normalized to organic carbon (log Koc) across seven theoretical soil types.

Main Results:

  • The model demonstrated good agreement with external literature data.
  • Predicted mobility classifications for 1661 pharmaceuticals, identifying 228 as very mobile and 671 as mobile.
  • Achieved 63.2% agreement with industry empirical classifications and 52.4% with literature data.

Conclusions:

  • The optimized machine learning model is a valuable tool for assessing pharmaceutical environmental mobility and risk.
  • The model aids in classifying the mobility of pharmaceuticals, supporting regulatory criteria adherence.
  • This approach can potentially be extended to other classes of organic micropollutants.